7/8/2019 Alert: Why CEL-SCI Corp. (CVM) Is Too Risky – Street


thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/ 1/8


Home  Blog 2  Uncategorized  Alert: Why CEL-SCI Corp. (CVM


ALERT: WHY CEL-SCI CO
TOO RISKY


/  0/  Sonya Colberg


ALERT: WHY CEL-SCI CORP. (CVM) IS TOO RISKY


24
APR  


Public Oath Clean Up Crew Legal Disclaimer


ALERT: WHY CEL-SCI COR



http://thestreetsweeper.org/

http://thestreetsweeper.org/blog-2/

http://thestreetsweeper.org/category/uncategorized/

http://thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/

http://thestreetsweeper.org/author/anshul/

http://thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/

http://thestreetsweeper.org/

http://thestreetsweeper.org/public-oath/

http://thestreetsweeper.org/clean-up-crew/

http://thestreetsweeper.org/legal-disclaimer/

http://thestreetsweeper.org/investment-tools/

http://thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/
7/8/2019 Alert: Why CEL-SCI Corp. (CVM) Is Too Risky – Street


thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/ 2/8


 


TheStreetSweeper issues an investor alert for Cel-Sci Corp. (NYSE: CVM).


The stock has risen precipitously and, in our opinion, faces a significant downside from today’s 


The Vienna, Virginia-based biotech’s chief experimental drug is Multikine (Leukocyte Interleukin
response system to fight head and neck cancer.


But CVM is way, way ahead of itself at this point. Look at the risks:


* INSTITUTIONS VIRTUALLY ABSENT: WAIT & SEE


Virtually no big banks or other institutions are holding this stock. Institutional interest in CVM is a


 


(Source: Nasdaq)


The institutions simply don’t believe in CVM. They would rather wait and see if the data suppor


Meanwhile, no analysts are covering the stock, according to Yahoo. And a Yahoo partner consi


*PAID PROMOTIONS


Companies curing diseases do not typically pay for promotions.


However, CVM’s CEO is featured in a February video interview with Proactive Investors, in which



https://www.nasdaq.com/symbol/cvm/institutional-holdings
7/8/2019 Alert: Why CEL-SCI Corp. (CVM) Is Too Risky – Street


thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/ 3/8


However, CVM s CEO is featured in a February video interview with Proactive Investors, in which
$25,000 fee for such promotions.


(Source: YouTube)


The disclaimer clearly states: “In exchange for publishing services rendered by the Company o
the promotion by the Company of the issuer in any Content on the Site, the Company receives
compensation in an amount equal to Twenty Five Thousand dollars ($25,000).”


The Coin Guild (here) also got the stock in front of investors via an April 9 story and the Midas Le
with the CEO on April 2.


(Source: YouTube)


CEO Geert Kersten – who earns $559,052 yearly, owns over 7% or 2.4 million shares and holds 1.3
July – makes a questionable suggestion in this interview … it’s a suggestion that we view as pro


He states, “What if we can now add the immune system to it in a non-toxic manner, and sudde


We don’t know how much Midas was compensated for the promotion, if anything, but the discl
may receive compensation:


“Midas Letter occasionally accepts fees for advertising and sponsorship from public companie
Letter may also receive compensation from companies affiliated with companies featured on 
invests in companies on this site and so readers should view all information on this site as bias


CVM has relied on promoters for years. In fact, in 2016,  notorious RedChip promoted CVM.



https://www.thecoinguild.com/investors-taking-another-look-at-cel-sci-corporation-cvm-after-recent-market-moves/52167

https://www.sec.gov/Archives/edgar/data/725363/000165495419003409/cvm_def14a.htm
7/8/2019 Alert: Why CEL-SCI Corp. (CVM) Is Too Risky – Street


thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/ 4/8


(Source YouTube)


Companies’ SEC filings sometimes refer to promoters as consultants or investor relations provi
$390k at recent prices) in just three months to investor relations consultants:


“During the three months ended December 31, 2018 the Company issued 62,784 restricted share
relations services.”


*HISTORY OF HIGH CASH BURN


The company has existed since 1983 and plowed through ~$330 million of stockholders’ money


Losses in 2018 alone hit $31.9 million and the cash needs are unending …


Filings show: “The Company has funded such costs with proceeds from loans and the public an
will be required to raise additional capital or find additional long-term financing to continue wi
not generated any revenue from product sales.”


If the study succeeds, CVM will have to raise untold millions. The company anticipates more 
unknown manufacturing costs.


If the study fails, CVM will still have to raise untold millions on more studies for new indication


In either case, stockholders can expect more watering down of their share value. And nobody k
or a few more decades to finalize.


*PERSISTENT UNKNOWNS


Despite the $200-plus million market valuation, CVM must wait to finalize the Phase III study of e


Of course, it’s unknown when the last sad event will take place so that scientists will be able to d
failed.


The CEO letter states:


“The enrollment of 928 patients in our Phase 3 clinical trial of Advanced Primary (just diagnosed



https://www.sec.gov/Archives/edgar/data/725363/000165495419001564/cvm_10q.htm
7/8/2019 Alert: Why CEL-SCI Corp. (CVM) Is Too Risky – Street


thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/ 5/8


The enrollment of 928 patients in our Phase 3 clinical trial of Advanced Primary (just diagnosed
completed in September of 2016. For the study to end we have to wait for 298 events (deaths) i
Based on published survival data, we had already expected to have reached the 298 events. In
Clinical Research Companies (CROS) running the Phase 3 study because we had not yet reach
While we do not like waiting, we also recognize that this may be a positive development for our
for not yet having reached 298 events. Let us explain to you why.


The primary objective of our Phase 3 study is to demonstrate that, by administering the Multikin
of care therapy (SOC), surgery followed by radiotherapy or followed by combined radiochemo
survival of the Multikine treated head and neck cancer patients. In a much smaller uncontrolled
overall survival even more. If Multikine does increase overall survival in our well controlled Phas
events.”


*SET UP TO DILUTE TODAY’S INVESTORS


Always dependent on loans and selling stock, CVM has registered to allow earlier shareholders
$0.83 per share. While CVM may boost cash by $24 million and warrant holders stand to profit h


DILUTION


As of September 30, 2018, we had a negative net book value. An investor purchasing shares in t
the difference between the price paid for the shares and our negative net tangible book value 


Between Jan. 1 and April 15, warrants for over 3 million shares were exercised, producing $8.9 m
5 million shares still loom over recent investors’ heads.


The company has not responded to TheStreetSweeper’s request for comment.


*CONCLUSION


CVM faces too many unknowns with its experimental drug, too much cash burn and promotion
come close to justifying today’s $200-plus million market valuation.


TheStreetSweeper expects this stock to swiftly plummet by at least 30 percent … still an extrem


* Important Disclosure: The owners of TheStreetSweeper hold a short position in CVM and stand
* Editor’s Note: As a matter of policy, TheStreetSweeper prohibits members of its editorial team 
that they cover. To contact Sonya Colberg, the author of this story, please send an email to stre


 


 


 Uncategorized



https://seekingalpha.com/symbol/CROS

http://thestreetsweeper.org/category/uncategorized/
7/8/2019 Alert: Why CEL-SCI Corp. (CVM) Is Too Risky – Street


thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/ 6/8


About Author


SONYA COLBERG


RELATED POSTS


14


Should investors trust Cool Holdings
(AWSM)? The phone re-seller’s stock
has been propelled by exaggerated
and misleading articles that Cool paid
$415,000 to promoters to create and
disseminate. While Cool is supposed to
disclose promotional payments, we
were only able to find disclosures in
promoters’ materials. But now, new...


/  0 Comments


/  Sonya Colberg


SHOULD WE TRUST COOL HOLDINGS
(AWSM)?


Uncategorized


04
OCT 








Read More 



http://thestreetsweeper.org/author/anshul/

http://thestreetsweeper.org/3pea-international-tpnl-frigid-drop-ahead//#respond

http://thestreetsweeper.org/3pea-international-tpnl-frigid-drop-ahead/

http://thestreetsweeper.org/should-we-trust-cool-holdings-awsm//#respond

http://thestreetsweeper.org/author/anshul/

http://thestreetsweeper.org/should-we-trust-cool-holdings-awsm/

http://thestreetsweeper.org/category/uncategorized/

http://thestreetsweeper.org/should-we-trust-cool-holdings-awsm/
7/8/2019 Alert: Why CEL-SCI Corp. (CVM) Is Too Risky – Street


thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/ 7/8


Comment


GIVE A REPLY


TheStreetSweeper issues an investor
alert for 3Pea International, Inc. (TPNL)!
This boring prepaid debit card
company is pushing toward a head-
scratching market valuation of around
$327 million … despite expected
revenue coming in at a mere fraction
of that, massive competition, virtually
no institutional interest and an
irrational P/E ratio. An...


/  0 Comments


/  Sonya Colberg


3PEA INTERNATIONAL (TPNL):
FRIGID DROP AHEAD?


Uncategorized


FEB 








Comment Name


Email


Read More 



http://thestreetsweeper.org/3pea-international-tpnl-frigid-drop-ahead//#respond

http://thestreetsweeper.org/author/anshul/

http://thestreetsweeper.org/3pea-international-tpnl-frigid-drop-ahead/

http://thestreetsweeper.org/category/uncategorized/

http://thestreetsweeper.org/3pea-international-tpnl-frigid-drop-ahead/
7/8/2019 Alert: Why CEL-SCI Corp. (CVM) Is Too Risky – Street


thestreetsweeper.org/alert-why-cel-sci-corp-cvm-is-too-risky/ 8/8





© 2009-2018 TheStreetSweeper | All Rights Reserved Developed and Mana



https://twitter.com/investorsbeware?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
